Showing results (191-200 of 216) with videos related to
Sort By:
Pageof 22
Molecular Systems Biology|May 7, 2014
Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancerLifeng Yang, Tyler Moss, Lingegowda S Mangala, et al.Frontiers in Oncology|May 9, 2022
Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer PatientsChao Fang, Wenfeng Fang, Liqin Xu, et al.Nature Metabolism|November 14, 2022
Myeloid-derived itaconate suppresses cytotoxic CD8<sup>+</sup> T cells and promotes tumour growthHongyun Zhao, Da Teng, Lifeng Yang, et al.Nature Communications|July 17, 2020
ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironmentChi-Lam Au-Yeung, Tsz-Lun Yeung, Abhinav Achreja, et al.Cancer Discovery|March 24, 2026
The oncogenic EGFR-SHC1 fusion confers insensitivity to EGFR-TKI via dual activation of N-EGFR kinase domain and C-SHC1 phosphorylation sites in lung cancerJiani Zheng, Shen Zhao, Jianhua Zhan, et al.Oncotarget|November 1, 2014
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapyWenfeng Fang, Jianwei Zhang, Shaodong Hong, et al.The Lancet Regional Health. Western Pacific|January 6, 2025
Consensus on the lung cancer management after third-generation EGFR-TKI resistanceQing Zhou, Hongyun Zhao, Shun Lu, et al.The Lancet. Oncology|June 1, 2024
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 studyYuxiang Ma, Yan Huang, Yuanyuan Zhao, et al.European Journal of Cancer (Oxford, England : 1990)|August 8, 2022
First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangementsYuxiang Ma, Hongyun Zhao, Jinhui Xue, et al.Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|April 25, 2021
[Chinese Experts Consensus on Immune Checkpoint Inhibitors
for Non-small Cell Lung Cancer (2020 Version)]Caicun Zhou, Jie Wang, Baocheng Wang, et al.Pageof 22